Irritable Bowel Syndrome
Conditions
Brief summary
This is an observational, open, longitudinal, multicentre study conducted in France. The study plans to enrol 119 patients with irritable bowel syndrome who will be included by about 50 general practitioners or gastroenterologists consulting in private offices. The treatment, Lactiplus® is a medical device, in the form of capsules containing L. gasseri LA806. The main objective of the study is to assess the effect of a 4-week treatment with the medical device on abdominal pain.
Detailed description
The study is designed as an observational post-market follow-up study, to confirm the performance of the medical device in real life conditions and document its safety profile. The eligible population corresponds to the population that could benefit from the treatment, according to the MD's instructions for use. Non-inclusion criteria prevent from including patients with other pathologies associated with gastro-intestinal troubles, who may beneficiate from more adequate treatments.
Interventions
DEVICELactiplus
capsules containing L. gasseri LA806
Sponsors
PiLeJe
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult (age ≥ 18 years) * Suffering from IBS (Rome IV criteria), whatever the predominant stool pattern, i.e recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with 2 or more of the following criteria: Related to defecation; Associated with a change in frequency of stool; Associated with a change in form (appearance) of stool; with symptom onset at least 6 months before diagnosis; * Having access to electronic tools (computer, tablet…) and an internet connection, allowing him to complete the online self-questionnaire.
Exclusion criteria
* Presence of clinical signs of alarm such as rectorrhagia, fever or recent unexpected weight loss or patient with suspicion or evidence of diseases that exclude IBS diagnosis: including but not limited to inflammatory gastrointestinal disease (e.g. Crohn's disease, ulcerative colitis), colorectal cancer, celiac disease, hyperthyroidism, intestinal infection, lactose intolerance, other malabsorption syndromes (e.g.: fructose), bile acid malabsorption; * History of abdominal surgery except appendectomy; * Allergy or hypersensitivity to one of the ingredients of the medical device; * Inability to fill self-questionnaires or to understand the information notice (cognitive or linguistic issues); * Participation to another clinical study or in the exclusion phase of a previous clinical study; * Refusal to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| assess the effect of a 4-week treatment with the medical device on abdominal pain | 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| assess the effect of a 4-week treatment with the medical device on the patient's quality of life | 4 weeks | — |
| assess the effect of a 4-week treatment with the medical device on the patient's intake of treatments (antidiarrheal, antispasmodic, laxative, pro/prebiotics, analgesics) | 4 weeks | — |
| assess the effect of a 4-week treatment with the medical device on digestive troubles | 4 weeks | global symptom score, intestinal symptoms (discomfort, distension/bloating, urgency to defecate, bowel habit, incomplete rectal emptying), Francis score, Clinical global impression of improvement |
| assess the satisfaction with the medical device | 4 weeks | — |
| assess the observance to the treatment and the intake of other medications | 4 weeks | — |
| assess the tolerance of the medical device | 4 weeks | — |
Countries
France
Outcome results
None listed